Literature DB >> 20655196

Protein kinase A-mediated phosphorylation of the RASSF1A tumour suppressor at Serine 203 and regulation of RASSF1A function.

Antje M Richter1, Undraga Schagdarsurengin, Matthias Rastetter, Katrin Steinmann, Reinhard H Dammann.   

Abstract

Epigenetic inactivation of the Ras-Association Domain Family 1A (RASSF1A) gene is one of the most frequent alterations detected in cancer. The tumour suppressor function of RASSF1A contributes to cell cycle progression, microtubule stabilisation and apoptotic signalling. Here we investigated the putative phosphorylation sites of RASSF1A and the functional consequences. RASSF1A is mainly phosphorylated at Serine 203 within its Ras association domain. Phosphorylation at this site is accomplished by protein kinase A (PKA) and is reduced and elevated by PKA-specific inhibitors and activators, respectively. Functionally, an alanine substitution of Serine 203 (S203A) slightly affected the microtubule stability mediated by RASSF1A (p<0.05). Interestingly, the inhibition of PKA and the S203A substitution of RASSF1A resulted in a reduced rate of apoptotic cells induced by RASSF1A. Moreover, RASSF1A-mediated upregulation of p21 and BAX was observed. This induction was reduced when the S203A substitution was present or when PKA activity was inhibited. In summary our data show that RASSF1A is phosphorylated by PKA and this phosphorylation may affect apoptotic signalling of RASSF1A. Thus epigenetic silencing of RASSF1A may counteract its proapoptotic function in cancer.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20655196     DOI: 10.1016/j.ejca.2010.06.128

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  11 in total

1.  A RASSF1A polymorphism restricts p53/p73 activation and associates with poor survival and accelerated age of onset of soft tissue sarcoma.

Authors:  Karen S Yee; Lukasz Grochola; Garth Hamilton; Anna Grawenda; Elisabeth E Bond; Helge Taubert; Peter Wurl; Gareth L Bond; Eric O'Neill
Journal:  Cancer Res       Date:  2012-03-02       Impact factor: 12.701

2.  Role of RASSF1A promoter methylation in the pathogenesis of hepatocellular carcinoma: a meta-analysis of 21 cohort studies.

Authors:  Yong-Shuang Li; Qiang Xie; Da-Ye Yang; Yuan Zheng
Journal:  Mol Biol Rep       Date:  2014-02-25       Impact factor: 2.316

Review 3.  Tumor suppressor C-RASSF proteins.

Authors:  Hiroaki Iwasa; Shakhawoat Hossain; Yutaka Hata
Journal:  Cell Mol Life Sci       Date:  2018-01-20       Impact factor: 9.261

4.  The cellular functions of RASSF1A and its inactivation in prostate cancer.

Authors:  Karishma S Amin; Partha P Banerjee
Journal:  J Carcinog       Date:  2012-02-17

5.  The tumor suppressor RASSF1A induces the YAP1 target gene ANKRD1 that is epigenetically inactivated in human cancers and inhibits tumor growth.

Authors:  Adriana P Jiménez; Annalena Traum; Thomas Boettger; Holger Hackstein; Antje M Richter; Reinhard H Dammann
Journal:  Oncotarget       Date:  2017-05-23

6.  A RASSF1A-HIF1α loop drives Warburg effect in cancer and pulmonary hypertension.

Authors:  Swati Dabral; Christian Muecke; Chanil Valasarajan; Mario Schmoranzer; Astrid Wietelmann; Gregg L Semenza; Michael Meister; Thomas Muley; Tamina Seeger-Nukpezah; Christos Samakovlis; Norbert Weissmann; Friedrich Grimminger; Werner Seeger; Rajkumar Savai; Soni S Pullamsetti
Journal:  Nat Commun       Date:  2019-05-13       Impact factor: 14.919

7.  New type of interaction between the SARAH domain of the tumour suppressor RASSF1A and its mitotic kinase Aurora A.

Authors:  T Szimler; É Gráczer; D Györffy; B Végh; A Szilágyi; I Hajdú; P Závodszky; M Vas
Journal:  Sci Rep       Date:  2019-04-03       Impact factor: 4.379

8.  The tumor suppressor RASSF10 is upregulated upon contact inhibition and frequently epigenetically silenced in cancer.

Authors:  A M Richter; S K Walesch; P Würl; H Taubert; R H Dammann
Journal:  Oncogenesis       Date:  2012-06-25       Impact factor: 7.485

9.  The SARAH Domain of RASSF1A and Its Tumor Suppressor Function.

Authors:  Claudia Dittfeld; Antje M Richter; Katrin Steinmann; Antje Klagge-Ulonska; Reinhard H Dammann
Journal:  Mol Biol Int       Date:  2012-04-09

10.  RASSF8 regulates progression of cutaneous melanoma through nuclear factor-κb.

Authors:  Jinhua Wang; Wei Hua; Sharon K Huang; Kun Fan; Ling Takeshima; Ying Mao; Dave S B Hoon
Journal:  Oncotarget       Date:  2015-10-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.